In our cohort, improved survival is specifically associated with a combination of subsets of CD127− CD39hi CD8+ Trm cells and CCR8hi ICOShi activated Tregs that are preferentially abundant in the tumor compared to the normal breast tissue and the peripheral blood from the same patient. The gene discussed is CD8A; the disease is neoplasm.